

Date: 17-11-2021
Version: 6.0

CBD Anti-Aging cream

Article No.: HASS0030

Product name: CBD Anti-Aging cream 50 ml

Ingredients: AQUA, ETHYLHEXYL STEARATE, GLYCERYL STEARATE, CETEARYL ALCOHOL, GLYCERIN, SODIUM ASCORBYL PHOSPHATE, BUTYROSPERMUM PARKII BUTTER, SORBITAN STEARATE, POLYSORBATE 60, PALMITIC ACID, STEARIC ACID, PHENOXYETHANOL, PARFUM, XANTHAN GUM, CANNABIDIOL, TOCOPHEROL, HELIANTHUS ANNUUS SEED OIL, RETINYL PALMITATE, ETHYLHEXYLGLYCERIN, SODIUM HYALURONATE.

Cannabidiol

Origin: Synthesis

CAS No.: 13956-29-1

IUPAC: 2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol

Molecular formula: C₂₁H₃₀O₂

Molecular weight: 314,46 g/mol

Description

CBD anti-aging cream.

Safety and precautions

If you are allergic to any of the product ingredients (see ingredients section for detailed information), individuals should consult their personal healthcare provider prior to use.

How to use

Use this CBD cream in the evening. After cleansing and toning, apply to face, neck, and upper chest. Avoid the area around the eyes.

General information

<i>Application and Use</i>	Skin product / cosmetic
<i>Appearance</i>	White / water look
<i>Shelf life after opening</i>	12 months
<i>Storing conditions</i>	Store at temperature: 8 – 25°C, dry and dark. Keep out of the reach of children. Protect from direct sunlight.
<i>Packaging</i>	50 ml frosted glass jar with White Cap*
<i>Dermatologically tested</i>	YES – ‘Harmless’
<i>Food Safety System</i>	FSSC22000 certified
<i>Cosmetic Safety System</i>	GMP
<i>Country of Origin</i>	Cosmetic from The Netherlands. CBD from Switzerland.

* Estimated sign (e) protocol.

Specification/Ingredients

<i>CBD (HPLC-UV)</i>	100 mg
<i>THC (HPLC-UV)</i>	detection limit is 0,05% (500 PPM)

Microbiologic assay

Next values are guidelines:

Enterobacteriaceae	<10 cfu/g
Total aerobic count	<100 cfu/g
Fungi/ mold	<100 cfu/g
yeast	<100 cfu/g

Legal notice

The information given in this publication is based on our current knowledge and experience, and may be used at your discretion and risk. Labocan does not hold any liability regarding the product or its use.

General

REACH

The material does not contain any substance meeting the criteria for PBT (Persistent, Bio accumulative, Toxic) or vPvB (very Persistent, very Bio accumulative) in accordance with Annex XIII of Regulation (EC) 1907/2006 (REACH) as amended.

CMR substances

The material does not contain a carcinogenic-, mutagenic or reprotoxic (CMR) substance (category 1A, 1B or 2) as listed under part 3 of Annex VI of Regulation (EC) 1272/2008 consolidated.

SVHC substances

The material does not fulfil any of the criteria as defined in article 57 of Regulation (EC) 1907/2006 (REACH) as amended, and is therefore not identified as SVHC (Substance of Very High Concern).

Other Contaminants

Based on the manufacturing and purification process, the material is free from contaminants such as asbestos, amines, nitrosamines, phthalates, bisphenol A, ethylene-oxide, or any constituent mentioned in Annex XIV / XVII of Regulation (EC) 1907/2006 (REACH) as amended.

The material does not contain heavy metals such as lead or mercury, or any other constituent mentioned in Annex II of Regulation (EC) 1223/2009 consolidated.

The material complies with CPMP/ICH/283/95 and EP 5.4 / USP <467> for residual solvents (class 2/3). During synthesis and purification, no class 1 solvents are used.

Animal testing

The material has not been tested by Labocan on animals, nor evaluated for safety through animal testing.

Allergens

No allergens or substances causing intolerances have been identified in the material, nor in the materials used for its production.

GMO's

No genetically modified organisms, nor products thereof have been used in the manufacturing process. It therefore complies to EC/1829/2003, consolidated, and EC/1830/2003, consolidated, for GMO's/GMO labeling.

Nanomaterials

No nanomaterials, nor products containing nanomaterials have been used in the manufacturing process. It therefore complies to (EC) 1169/2011, consolidated, for nanomaterials/nanomaterial labeling.

TOXICOLOGICAL INFORMATION

Tested on the actual material

The material has been found non -irritant/-damaging to the eye in the **Bovine Corneal Opacity and Permeability assay** (OECD guideline 437), and the **EpiOcular™** test (OECD guideline 492).

The material has been found non -irritant/-corrosive (to the human skin) in the human skin model test on **EpiDerm™** as a skin model (OECD guideline 431, Regulation (EC) 440/2008), and **EpiSkin™** (OECD guideline 439, Regulation (EC) 440/2008) as the skin models.

The material CBD was found to be nonirritant with less than 15 genes overexpressed. Under the experimental conditions of this **SENS-IS assay** study CBD was found a weak sensitizer.

General, based on literature data

LD50 values (intravenous) have been established in mice (50 mg/kg) and dogs (> 254 mg/kg). The LD50 value after intravenous administration to rhesus monkeys was 212 mg/kg. An oral LD50 has not been established, but it was shown that an oral dose up to 10 g/kg was required to initiate severe intoxications in the monkeys.

Cannabidiol failed to induce teratogenic- or mutagenic effects, as tested in numerous studies.

Due to the high log P (water/octanol) value of 5.8, cannabidiol after dermal application is unlikely to penetrate largely into the systemic circulation. Using a human skin permeation model, an average flux of 0.73 nmolcm⁻²h⁻¹ was established for cannabidiol dissolved in mineral oil.

Based on studies done in humans (minimum duration 30 days), an oral NOAEL (No-Observed-Adverse-Effect-Level) of 180 – 300 mg/day up to 1200 – 1500 mg/day can be established.

I. van Delft, Quality manager

